Evidence map›Paper›PMID 39764418›Full record

ArticleExploration of targeted anti-tumor therapy2024

Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer.

Hortense De Saint Basile, Reza Elaidi, Zineb Maaradji, Hélène Blons, Rym BenDhiab, Laure Gibault, Elizabeth Fabre

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration of targeted anti-tumor therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hortense De Saint BasileDepartment of Thoracic Oncology, Georges Pompidou European Hospital, Paris Cité University, AP-HP, CARPEM, 75015 Paris, France.
Reza ElaidiDepartment of Thoracic Oncology, Georges Pompidou European Hospital, 75015 Paris, France.
Zineb MaaradjiDepartment of Thoracic Oncology, Georges Pompidou European Hospital, Paris Cité University, AP-HP, CARPEM, 75015 Paris, France.
Hélène BlonsDepartment of Molecular Biology, Georges Pompidou European Hospital, Paris Cité University, AP-HP, CARPEM, 75015 Paris, France.
Rym BenDhiabDepartment of Thoracic Oncology, Georges Pompidou European Hospital, Paris Cité University, AP-HP, CARPEM, 75015 Paris, France.
Laure GibaultDepartment of Pathology, Georges Pompidou European Hospital, Paris Cité University, AP-HP, CARPEM, 75015 Paris, France.
Elizabeth FabreDepartment of Thoracic Oncology, Georges Pompidou European Hospital, Paris Cité University, AP-HP, CARPEM, 75015 Paris, France.ORCID https://orcid.org/0000-0002-1244-873X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Immune checkpoint inhibitors improved the survival of advanced non-small cell lung cancer. However, only 20% of patients respond to these treatments and the search for predictive biomarkers of response is still topical. The objective of this work is to analyze the anti-PD-1 monotherapy benefit based on genetic alterations diagnosed by next generation sequencing (NGS), in advanced non-small cell lung cancer. Methods: Patients with advanced non-small cell lung cancer treated with immunotherapy were retrospectively included in this monocentric study. Clinical data, immunohistochemical expression of PD-L1 and molecular data, with a 22-genes NGS panel, were collected. Results: 107 patients were included. The median age was 65 years [59; 73], 70 were men (65%), 96 had adenocarcinoma (90%), 33 were receiving a first line (31%). 54 patients had KRAS mutation (50%) and 56 had TP53 mutation (52%). The remaining mutations were present in fewer than 10 patients. There was no statistically significant differences in median of progression-free or overall survival based on KRAS-only, TP53-only or KRAS-TP53 mutations co-mutated compared to double wild-type patients ( Conclusions: The search for a predictive composite biomarker remains a major issue in the coming years.

Indexed as

biomarkercheckpoint inhibitorsco-mutationsKRASmutationsNGSNon-small cell lung cancerTP53

Identifiers

PMID39764418
PMCPMC11702263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.